HARMONY Alliance Partners and Associated Partners have successfully demonstrated the power of Big Data to improve the treatment of blood cancers in 2023. Research and data science teams utilized the HARMONY Big Data Platform with its innovative data analytic tools to address pressing clinical inquiries.

---

Selection of 2023 milestones

• What is the prognosis after hematopoietic stem cell transplantation in patients with relapsed or refractory acute lymphoblastic leukemia (ALL)? 
• Which factors are associated with long-term survival in patients with acute promyelocytic leukemia (APL)? 
• How can we identify children with a risk of relapse of childhood acute lymphoblastic leukemia (ALL) due to minimal residual disease? 
• How can machine learning help to provide individualized prediction of outcomes after first complete remission in adult acute myeloid leukemia (AML) patients? 
• Can data in the HARMONY Big Data Platform supplement the control arm in randomized controlled clinical trials in acute myeloid leukemia AML? 
• Which factors predispose patients with chronic lymphocytic leukemia (CLL) to an increased risk of developing other malignancies?
• Can treatment with lenalidomide be discontinued in some patients with myelodysplastic syndrome (MDS)? 

---

Seven years of intense collaboration

Click on the images or links below and listen to our partners sharing their vision and experiences. 

  

Link to video >                                                                                             Link to video >

---

Sharing data and exploration tools

We are reaping the benefits of our research infrastructure that facilitates data-driven research projects. Our data lake has expanded considerably, now having identified more than 165,000 data sets and having transferred over 115,000 anonymized data to the HARMONY Big Data Platform. 

Our cutting-edge data processing pipeline ensures data safety and quality, as well as patient privacy. We developed more sophisticated data analytic tools, allowing scientists to answer research questions that cannot be addressed with other methods. 

---

Sharing knowledge

Our experts have shared their knowledge at international events, through our community and our communication channels in 2023. We actively participated in the annual congresses of the European Hematology Association (EHA2023), the European Myeloma Network (EMN2023), the European Society for Blood and Marrow Transplantation (EBMT2023) and the American Society for Hematology (ASH2023). 

We raised awareness of the meaning of ‘Big Data’ in clinical blood cancer research for patients during Blood Cancer Awareness Month in September 2023.

---

Ready for the future

Over the past seven years, the HARMONY Alliance (IMI-HARMONY and IMI-HARMONY PLUS) has revolutionized the use of big data to accelerate developments in treating and managing patients with Hematological Malignancies. We have built a robust, open, collaborative research community that leverages big data to improve patient care.
 
The EU grant phase (European Commission’s Innovative Health Initiative, IHI, formerly known as IMI) that made this possible will end in 2024. Thanks to the strong commitment and drive of the multi-stakeholder partners and members involved in HARMONY, we have the unique opportunity to continue our work as a non-profit, collaborative research foundation. This new foundation will build upon the achievements of the HARMONY Alliance and bring hematology research and patient care to the next level.

---

Receive the latest news. Click here to subscribe!